Forte Biosciences (FBRX) EV to EBITDA (2017 - 2026)
Powered by 
Analysis
Forte Biosciences (FBRX) EV to EBITDA (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.57 |
| Mar 31, 2026 | -17.99 |
| Dec 31, 2025 | -11.24 |
| Sep 30, 2025 | -9.44 |
| Jun 30, 2025 | -4.55 |
| Mar 31, 2025 | -2.64 |
| Dec 31, 2024 | -1.07 |
| Sep 30, 2024 | 0.70 |
| Jun 30, 2024 | -0.02 |
| Mar 31, 2024 | -0.21 |
| Dec 31, 2023 | 1.14 |
| Sep 30, 2023 | 2.17 |
| Jun 30, 2023 | 0.94 |
| Mar 31, 2023 | 2.14 |
| Dec 31, 2022 | 4.80 |
| Sep 30, 2022 | 6.30 |
| Jun 30, 2022 | 6.41 |
| Mar 31, 2022 | 7.35 |
| Dec 31, 2021 | 3.17 |
| Sep 30, 2021 | 0.26 |